Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
Introduction of certain types of successor drugs as the original product nears patent expiration has "caught the attention" of individuals at FTC, Commissioner Harbour tells BIO annual conference. A company's history and methods of engaging in this practice to blunt generic competition could open it up to agency scrutiny, she says.